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Bayesian meta-analytical methods to
incorporate multiple surrogate endpoints
in drug development process
Sylwia Bujkiewicz,a* John R. Thompson,b Richard D. Rileyc
and Keith R. Abramsa
A number of meta-analytical methods have been proposed that aim to evaluate surrogate endpoints. Bivariate
meta-analyticalmethods can be used to predict the treatment effect for the final outcome from the treatment effect
estimatemeasured on the surrogate endpoint while taking into account the uncertainty around the effect estimate
for the surrogate endpoint. In this paper, extensions to multivariate models are developed aiming to include
multiple surrogate endpoints with the potential benefit of reducing the uncertainty when making predictions. In
this Bayesian multivariate meta-analytic framework, the between-study variability is modelled in a formulation
of a product of normal univariate distributions. This formulation is particularly convenient for including
multiple surrogate endpoints and flexible for modelling the outcomes which can be surrogate endpoints to the
final outcome and potentially to one another. Two models are proposed, first, using an unstructured between-
study covariance matrix by assuming the treatment effects on all outcomes are correlated and second, using a
structured between-study covariance matrix by assuming treatment effects on some of the outcomes are
conditionally independent. While the two models are developed for the summary data on a study level, the
individual-level association is taken into account by the use of the Prentice’s criteria (obtained from individual
patient data) to inform the within study correlations in the models. The modelling techniques are investigated
using an example in relapsing remitting multiple sclerosis where the disability worsening is the final outcome,
while relapse rate and MRI lesions are potential surrogates to the disability progression. © 2015 The Authors.
Statistics in Medicine Published by John Wiley & Sons Ltd.
Keywords: Bayesian analysis; multivariate meta-analysis; multiple outcomes; surrogate endpoints; multiple
sclerosis
1. Introduction
Surrogate endpoints are increasingly being investigated as candidate endpoints in randomised controlled
trials where measuring a primary outcome of interest may be too costly, too difficult to measure or
require long follow-up time. Prior to the use of surrogate endpoint for trial design or decision-making for
regulatory or reimbursement purposes, such endpoints need to be validated. The validation takes place
on three levels: by establishing a biological plausibility of the association between outcomes, assessing
association between outcomes at the individual level and validating the surrogate endpoints at the study
level to assess them as predictors of clinical benefit measured by the final outcome [1]. It has been
established that methods based on a single clinical trial are not sufficient and surrogate endpoints have to
be validated based on a number of clinical trials in a meta-analytic framework [1, 2].
A number of meta-analytical methods have been proposed that aim to evaluate treatment effects on
surrogate endpoints as predictors of the effect on a target outcome. Methods by Buyse et al. [3] were
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developed to model surrogate endpoints at the arm level by extending the ideas developed by Prentice
[4] to a meta-analytic framework, while those by Daniels and Hughes [2] are focussed on modelling the
relationship between relative treatment effects on outcomes. The former are developed in a frequentist
approach while the latter in a Bayesian framework. Various extensions to meta-analytic approaches
to evaluating surrogate endpoints have been developed, for example, for the time-to-event data by
Burzykowki et al. [5] extended to a Bayesian framework by Renfro et al. [6].
Most methods developed to date are designed to evaluate single surrogate endpoints. In the summary
of a National Institutes of Health Workshop on the use of surrogate endpoints, Gruttola et al. [7] made
a number of recommendations for future research that included, for example, development of models
that can accommodate measurement error, missing data and multiple surrogate endpoints and/or multiple
clinical outcomes. Methods for evaluating multiple surrogate endpoints were proposed by Xu and Zeger
[8] for time-to-event data modelled jointly with multiple biomarkers measured longitudinally but were
mainly limited to individual-level data. Other examples of validatingmultiple surrogate endpoints include
the plasma HIV-1 RNA and CD4+ lymphocytes as predictors of progression to AIDS in HIV-positive
patients [9, 10] and relapse rate and number of active lesions in the brain as predictors of disability
progression in relapsing remitting multiple sclerosis (RRMS) [11], which usedmethods that did not allow
for inclusion of the measurement error for the surrogate endpoint.
Bivariate meta-analytical methods can be used to predict the treatment effect on the target outcome
from the effect on surrogate endpoint (while taking into account the uncertainty around the treatment
effect on surrogate endpoint ignoring of which can impact on predictions [12]) as well as to combine
evidence on treatment effect on both outcomes by ‘borrowing of strength’ across outcomes when
evaluating new health technologies [13,14]. Extending such methods to multivariate models can be used
to evaluate multiple surrogate endpoints as joint mediators of clinical benefit with a potential advan-
tage of increasing the precision of predictions. Multivariate meta-analysis models require within-study
correlations between multiple effect estimates which are usually not available but need to be accounted
for [13, 15]. If individual patient data (IPD) are not available, but results of the Prentice’s criteria for
surrogacy are, then we propose to use those criteria to obtain the within-study correlations.
Models considered in this paper build on a multivariate meta-analysis model of mixed outcomes devel-
oped by Bujkiewicz et al. [16], where the between-study covariance is parameterised in a formulation of
a product of univariate normal distributions. In this model, an assumption of conditional independence
between outcomes was used to simplify the model by putting a structure on the between-study covariance
matrix. Building on this model, we extend it to two alternative models. In the first case, the assumption is
relaxed to allow for full unstructured covariance to be modelled in a product normal formulation, where
multiple surrogate endpoints and the final outcome are correlated and hence one surrogate endpoint can
also act as a surrogate to the other. In the second case, we propose an alternative parameterisation to
the one by Bujkiewicz et al. [16], which also assumes conditional independence between some of the
outcomes (by putting a structure on the between-study covariance) but is more suitable for defining
criteria for surrogacy. In both models, the product normal parameterisation offers the possibility of
describing the criteria for surrogacy in a greater detail compared with providing a between-study
correlation only, which would be the case when modelling the covariance structure directly. The
modelling techniques are investigated using example in RRMS, where the disability worsening is the
final outcome, while relapse rate and number of active MRI lesions have been considered potentially
good surrogates to the disability progression [11, 17].
In the remainder of this paper, the two models (with unstructured and structured covariance matrix)
are introduced in Section 2, where in addition to this a model for obtaining the within-study correlation
from published Prentice’s criteria is described. In Section 2.7, the use of software is briefly reported,
which is then followed by the application of the methods to data specific to the example in RRMS which
is presented together with the results in Section 3. Simulation study investigating the robustness of the
methods to the normality assumption as well as the performance of the methods is described in Section 4.
Extensions of the two approaches to themultivariate case are developed in Section 5. The paper concludes
with a discussion of methods in Section 6.
2. Trivariate random effects meta-analysis with application to surrogate endpoints
Suppose in each study i, we have three estimates of treatment effect observed on each of the three
outcomes Y1i, Y2i and Y3i, where Y3 is the treatment effect estimate for the final clinical outcome, while
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Y1 and Y2 are intermediate surrogate endpoints. Assuming the treatment effect estimates for the three
outcomes in each study have a trivariate normal sampling distribution, the model can be written as
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In the aforementioned model, Y1i, Y2i and Y3i are assumed to be estimates of the correlated true
treatment effects 𝜇1i, 𝜇2i and 𝜇3i with corresponding within-study covariance matrices 𝚺𝐢 of the estimates
(comprising of the within-study correlations 𝜌jkwi between the estimates Yji and Yki and within-study
standard deviations 𝜎ji corresponding to each estimate Yj, for each outcome j = 1, 2, 3 and study i). These
true study-level effects are assumed to follow a trivariate normal distribution with means
(
𝛽1, 𝛽2, 𝛽3
)
and covariance 𝐓 (comprising of the between-study correlations 𝜌jkb between the true treatment effects 𝜇j
and 𝜇k and between-study standard deviations 𝜏j corresponding to each true effect 𝜇ji, j = 1, 2, 3 in
each study i). In this hierarchical framework, Equations (1) and (2) describe the within-study and the
between-study models, respectively.
In the remainder of this Section, the procedure for the use of the aforementioned model for the purpose
of the validation of the surrogate endpoints is described in Section 2.1. The estimation of the variances for
missing outcomes (omitted for the purpose of the validation) and the within-study correlations (which are
not reported for any of the studies but can be obtained from reported individual-level surrogacy criteria)
is described in Section 2.2. This is followed by setting out scenarios for modelling surrogate endpoints,
by the use of an unstructured or structured between-study covariance matrix, in Section 2.3 followed by
the details of the modelling in the product normal formulation with the unstructured covariance matrix T
in Section 2.4 and structured covariance in Section 2.5. The section is concluded by defining surrogacy
criteria for the models in Section 2.6 and remark on the software use in Section 2.7.
2.1. Application of multivariate meta-analysis to evaluating surrogate endpoints
2.1.1. Using multivariate meta-analysis to make predictions from surrogate outcomes. Traditionally,
multivariate meta-analysis is used to estimate pooled effects for multiple outcomes from multiple studies
by taking into account the correlation between the outcomes. Studies included in a multivariate meta-
analysis may all report all of the outcomes, or alternatively, it is permitted that some of the studies report
only a subset of outcomes under a missing at random assumption. In the latter case, the unreported
outcomes can be predicted for each of the studies by taking into account the correlation between the
outcomes. In a Bayesian framework, this can be achieved by coding the unreported outcomes as missing,
which are then predicted by the Markov chain Monte Carlo (MCMC) simulation of the model (1)–(2)
[16]. This framework can be adopted to validating surrogate endpoints (at a study level).
2.1.2. Using cross-validation to examine the accuracy of predictions from multivariate meta-analysis.
The study-level validation is conducted in the form of cross-validation similar to the ‘leave-one-out’
approach as for example in Daniels and Hughes [2], except instead of taking one study out, only the
estimate for the final outcome in one study is taken out. For all of the studies in the data set, one study
at a time, the following procedure is conducted. For a given study, the estimate of the treatment effect
on the final outcome is omitted (and coded as missing as if this particular study was a new study with
the final outcome yet unknown). Then the multivariate meta-analytic framework (1)–(2) is applied to
the data including the study with the estimates of the effects on candidate surrogate endpoints known
but on the final outcome missing. This missing effect is then predicted by the MCMC simulation from
observed effect(s) on surrogate endpoint(s) by taking into account the data on all outcomes from the
remaining studies and the relationship between the effects on all outcomes defined by the multivari-
ate meta-analytic model. The observed estimate is then compared with the predicted value by checking
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 1063–1089
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whether the value of the observed estimate falls within the predicted interval. To see if this framework
will give reliable predictions for the omitted final outcome in one study, this procedure is repeated for
each study i (i = 1,… , I), giving I comparisons of how the predictions from the surrogate endpoints
using the multivariate modelling approach perform. Ideally, we want to compare the performance of the
model in predicting the true effect 𝜇3n in a new study n. But we do not know what the true effect is, so
instead, we predict Ŷ3n and then compare the estimate Y3n with the predicted interval with the variance
𝜎23n + var(?̂?3n|Y1n,Y2n, 𝜎1n, 𝜎2n,Y1(−n),Y2(−n),Y3(−n)), where Y1(2,3)(−n) denote the data from the remaining
studies without the validation study n.
Post the validation process, when endpoints are established as surrogate endpoints to the final outcome,
this multivariate meta-analytic framework can be used to predict treatment effect on the final outcome
from those on the surrogate endpoints in a new study, for example, for the purpose of early decision
making process, in particular when the treatment effect(s) on surrogate endpoint(s) is(are) measured early
compared with the final outcome.
2.2. Obtaining within-study variances and covariances
The within-study variability in each study i is represented by the within-study covariance matrices Σi
in model (1) which are assumed to be known. In practice, only the variances can be obtained from the
reported data by calculating standard errors squared, while the within-study correlations between the
treatment effect estimates are usually not reported. Also the within-study variance of the treatment effect
for the final outcome in the study in which this effect is omitted in the cross-validation (Section 2.1 ) will
be unknown at the validation stage. In this case, the variance will be coded as missing and a distribution
has to be placed over a missing node (required if usingWinBUGS for MCMC simulation). Uniform prior
distribution was placed on the missing variance, 𝜎21,(2,3) ∼ unif (0.001, 1000), which was recommended
as a non-informative prior distribution for variances by Lambert et al [18] (who also list other suitable
prior distributions).
2.2.1. Within-study covariances. Calculation of the within-study covariances between estimates Yji
and Yki, Σi[j, k], for each pair of outcomes j, k in each study i requires knowledge of the estimate of
the within-study correlations 𝜌jkwi. These correlations between estimates of the treatment effects can be
obtained by bootstrapping [2] (or double bootstrapping for correlation with uncertainty [16]) of the IPD
from all of the studies or a subset of studies in the meta-analysis. Here, we consider an alternative
approach where IPD is not available for any of the studies, but surrogacy on individual level has been
investigated and reported by the use of Prentice’s criteria.
To obtain the within-study correlations 𝜌jkwi between each pair of the treatment effect estimates Y1i,
Y2i and Y3i, calculated as a difference between two measurements in the experimental and control arms,
we adopt an approach similar to the one developed by Wei and Higgins [19] who used a bivariate delta
method to express the within-study covariance between treatment effects, such as, for example, log odds
ratios, in terms of the covariances between outcomes, such as the probabilities (or risks) and using a
correlation between the outcomes from the literature. Here, this approach is adopted in a simpler form
by representing the within-study covariance between treatment effects in terms of the variances and
correlations between the effects on specific treatment arms. In the case considered here, this is suffi-
cient (and does not require the use of the bivariate delta method) as the correlations between effects on
arm level can be obtained from Prentice’s criteria of association of outcomes modelled on the absolute
normal scale. However, to estimate the variances of effects in each arm, sufficient data need to be avail-
able, such as two by two table (or log odds of event with corresponding standard error) for Binomial
outcomes or event rates and number of individuals (or log rates with corresponding standard errors) for
Poisson outcomes.
The within-study covariances between treatment effects on each pair of normally distributed outcomes
j, k (j ≠ k; j, k = 1, 2, 3) can be expressed in terms of the covariances between arm-specific effects:
Σi[j, k] = Σi[k, j] = Cov
(
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)
= Cov
(
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= Cov
(
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where Yji (Yki) is the treatment difference on outcome j (k) (such as a mean difference or log odds ratio),
Xaji (Xaki) are the absolute treatment effects on outcome j (k) (such as mean or log odds) in arm a (where
e and c stand for an experimental and control arm, respectively) in study i and
Cov(Xaji,Xaki) =
√
Var(Xaji)Var(Xaki)𝜌∗jki (4)
where 𝜌∗jki is the correlation between the absolute effects measured on outcomes j and k in each study i,
which can be obtained from reported surrogacy criteria as discussed in the succeeding section.
2.2.2. Within-study correlations. Taking into account the above derivation of the within-study covari-
ance, the within-study correlation can be obtain from
𝜌
jk
wi =
Σi[j, k]√
Σi[j, j]Σi[k, k]
=
(√
Var(Xeji)Var(Xeki) +
√
Var(Xcji)Var(Xcki)
)
𝜌∗jki√
𝜎2ji𝜎
2
ki
, (5)
where, as noted in the previous section, it is assumed that the variances of Xaj(k)i can be obtained from
the data (for example from two by two tables for binary outcomes). Therefore, only the correlations 𝜌∗jki
between the effects on arm level need to be estimated in order to calculate the within-study correlations,
𝜌
jk
wi, between treatment effects on each pair of outcomes j and k. Consider that Xji is an average measure-
ment on surrogate endpoint Si, that is, Xji = E(Si) and Xki is an average measurement on final endpoint
Fi, that is, Xki = E(Fi), and 𝜌∗jki is the correlation between those average effects. Noting that for normally
distributed outcomes, the correlation between the normally distributed individual observations equals the
correlation between the means ensures that 𝜌∗jki should equal the correlation between the individual-level
responses for S and F that can be obtained by modelling individual patient data.
When investigating the association on individual level between surrogate endpoint Sim and final out-
come Fim for patient m under treatment Zim in a study i, Prentice’s criteria can be used to evaluate
surrogacy. The four Prentice’s criteria require that (i) there is significant treatment effect on the surrogate
endpoint, (ii) there is significant treatment effect on the final outcome, (iii) surrogate endpoint has a sig-
nificant impact on the final outcome and (iv) the effect of treatment on the final outcome is fully mediated
by the surrogate endpoint [1, 4]. Similarly as by Burzykowski, Molenberghs and Buyse [1], the first two
criteria for the normally distributed outcomes can be written for each study i in the following model:
Sim = 𝜇Si + 𝛼iZim + 𝜖Sim,
Fim = 𝜇Fi + 𝛽iZim + 𝜖Fim
(6)
with correlated error structure
Ω =
(
𝜔iSS 𝜔iSF
𝜔iFF
)
,
and hence, the correlation between Si and Fi, referred to by Buyse and Mollenberghs [20] as adjusted
association (between Si and Fi after adjustment for the treatment Zi), equals 𝜌ZiSF =
𝜔iSF√
𝜔iSS𝜔iFF
. This is
the correlation in the individual-level response for S and F which as noted above equals the correlation
between the means, in this case between E(Sim) and E(Fim) and hence between Xji and Xki. Thus the
correlation 𝜌ZiSF equals the correlation 𝜌
∗
jki between the absolute effects in (4) if, for example, j = S and
k = F. Also the average treatment effects 𝛼i and 𝛽i on the two outcomes are the treatment effect estimates
Yji and Yki in study i. The correlation 𝜌ZiSF is required to estimate the within-study correlation 𝜌
jk
wi, which
can be obtained from the fourth Prentice’s criteria [4] which Burzykowski, Molenberghs and Buyse [1]
propose to verify through the conditional distribution of the final outcome conditional on the treatment
and the surrogate endpoint,
Fim = ?̃?iF + 𝛽iSZim + 𝛾iZSim + 𝜖Fim, (7)
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 1063–1089
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where 𝛽iS = 𝛽i − 𝛼i𝜔iFS∕𝜔iSS and 𝛾iZ = 𝜔iFS∕𝜔iSS. This criterion requires that if all treatment effect
is mediated by the surrogate endpoint S then 𝛽iS should be zero. Rearranging the terms for 𝛽iS gives
𝜔iFS = 𝜔iSS(𝛽i − 𝛽iS)∕𝛼i, which substituted into the formula for the adjusted association 𝜌ZiSF gives
𝜌ZiSF =
𝛽i − 𝛽iS
𝛼i
√
𝜔iSS∕𝜔iFF. (8)
The parameters 𝛼i, 𝛽i, 𝜔iSS and 𝜔iFF can be obtained by fitting model (6) to the patient data on responses
S and F.
To complete the individual-level validation, the third Prentice’s criteria can be verified by
Fim = 𝜇i + 𝛾iSim + 𝜖im, (9)
with further details discussed by Burzykowski, Molenberghs and Buyse [1].
In the trivariate meta-analysis, the within-study correlations between treatment effects need to be
estimated for each pair of outcomes. To do this using the above criteria, one of the outcomes in each
pair is considered a surrogate endpoint to other outcome. Ideally, the within-study correlations (or the
Prentice’s criteria from which the correlations derive) should be obtained from the IPD from each study
in the meta-analysis. When IPD is available from each of the studies, the within-study correlation can be
calculated directly. However, in the absence of the data, it may be possible to obtain the Prentice’s criteria
corresponding to the data from each (or some) of the studies (or some of the studies in the meta-analysis).
The Prentice’s criteria provide both the assessment of surrogacy on the individual level as well as
sufficient information to obtain the within-study correlations. This approach is illustrated in Section 3,
where the Prentice’s criteria published in literature for one of the studies included in the meta-analysis
for themotivating example in RRMS are used to estimate thewithin-study correlation. Note that establish-
ing the within-study correlation does not guarantee causal relationship between the treatment effects on
surrogate and final outcomes. Research developments on causality of surrogate endpoints are highlighted
in the Discussion section.
2.3. Scenarios for modelling of surrogate endpoints
Two scenarios for modelling the surrogate endpoints are considered here. In the first scenario, true
treatment effects, 𝜇ji, on all the outcomes are assumed correlated as shown in Figure 1a. In this case,
the between-study covariance matrix T in the model (2) is unstructured and can be modelled directly,
by either placing inverse Wishart prior distribution on T , by Cholesky or spherical decomposition
[21] (and placing separate prior distributions on the between-study correlations and standard deviations)
or by re-parameterising the between-study model in the product normal formulation of the series of uni-
variate conditional distributions. The latter approach has a number of advantages. In contrast to modelling
it directly by the use of Wishart prior distribution, the product normal formulation allows direct con-
trol over the prior distributions on all elements of the between-study covariance matrix (between-study
Figure 1. Scenarios for modelling surrogates endpoints: (a) all outcomes correlated giving unstructured
covariance matrix T , (b) final outcome conditionally independent from the first surrogate endpoint conditional
on the second giving structured covariance matrix equivalent to the precision matrix T−1 with element [1, 3] equal
to zero.
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standard deviations and correlations). It also allows to describe some association criteria which helps to
assess the surrogacy in more detail compared with obtaining only between-study correlation.
In the second scenario, shown in Figure 1b, in which the treatment effects on multiple outcomes
may (but do not have to) be assumed to be measured sequentially in time, assumption is made that the
treatment effect on the final outcome is conditionally independent from the effect on the first surro-
gate endpoint conditional on the effect on the second surrogate. This assumption puts a structure on the
between-study covariance matrix T resulting in element [1, 3] of the precision matrix T−1 being equal to
zero. This approach leads to a reduced number of parameters to estimate and is easier to implement, in
particular when dealing with multiple outcomes beyond the trivariate case (for details see Sections 5.1
and 5.2).
2.4. Product normal formulation with unstructured covariance matrix
For the first scenario of the true treatment effects 𝜇ji on all outcomes being correlated, represented graph-
ically in Figure 1a, the between-study covariance has an unstructured form. The between study model
(2) for this scenario is re-parameterised in the product normal formulation of the series of univariate
conditional distributions:
⎧⎪⎪⎨⎪⎪⎩
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(
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2
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(10)
Instead of placing independent non-informative prior distributions on all the parameters and hyper-
parameters of the model, relationships between these parameters and the elements of the between-study
covariance matrix are derived to allow to take into account the inter-relationship between the parameters.
These relationships have the following forms:
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which are obtained by following the procedure described in detail in Section 5.1 for N-dimensional
case. Having established them allows to place prior distributions on the between-study standard devi-
ations and correlations, which is an easier task as the plausible range of values for these parameters
are known or can be obtained from external sources of information (see, for example, Higgins and
Whitehead [22] or Bujkiewicz et al. [16]). By placing prior distributions on these parameters, for exam-
ple, 𝜌12(13,23)b ∼ dunif (−1, 1), 𝜏1(2,3) ∼ N(0, 10)I(0, ) (normal distribution truncated at value zero),
the above derived relationships give the implied prior distribution on the parameters 𝜆21, 𝜆31 and 𝜆32
and hyper-parameters 𝜓1, 𝜓2 and 𝜓3. The remaining parameters are given ‘vague’ prior distributions,
𝜂1 ∼ N(0, 1000), 𝜆20(30) ∼ N(0, 1000).
Note that the pooled effects 𝛽1(2,3) on the three outcomes in model (2) are also directly linked to the model
(10); 𝛽1 = 𝜂1, 𝛽2 = 𝜆20 + 𝜆21𝛽1 and 𝛽3 = 𝜆30 + 𝜆31𝛽1 + 𝜆32𝛽2. It is possible to center the true effects on
surrogate endpoints (by replacing 𝜇ji with (𝜇ji − 𝜇ji) in the third and fifth line of formula 10, which can
be useful if there are problems with autocorrelation) in which case the intercepts would equal the pooled
effects; 𝛽2 = 𝜆20 and 𝛽3 = 𝜆30.
2.5. Product normal formulation with structured covariance matrix
A simplifiedmodel can be used by assuming conditional independence between treatment effects on some
of the outcomes. For example, we can consider a situation where treatment effect is measured on different
outcomes sequentially in time (or on the same outcome repeatedly in time). For example, if treatment
effect on first outcome is measured at 12 months, second at 24 months and third at 36 months, then it may
be conceivable to assume that the effect on the final outcome may be conditionally independent from the
effect on the first outcome conditional on the second. This scenario, described in Figure 1b, leads to a
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 1063–1089
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simplified between-study model with the true effect on the final outcome now conditional on the effect
on the second surrogate endpoint only:
⎧⎪⎪⎨⎪⎪⎩
𝜇1i ∼ N
(
𝜂1, 𝜓
2
1
)
𝜇2i ∣ 𝜇1i ∼ N
(
𝜂2i, 𝜓
2
2
)
𝜂2i = 𝜆20 + 𝜆21 𝜇1i
𝜇3i ∣ 𝜇2i ∼ N
(
𝜂3i, 𝜓
2
3
)
𝜂3i = 𝜆30 + 𝜆32 𝜇2i,
(12)
The assumption of conditional independence of the true treatment effects on outcomes three and one,
𝜇3 and 𝜇1, conditional on the effect on outcome two, 𝜇2 puts a structure on the covariance matrix giving
the corresponding element ({1, 3}) of the inverse covariance (precision) matrix equal to zero. This means
that partial correlation 𝜌13|2b = 0. Because the partial correlation between 𝜇1 and 𝜇3 (adjusted for 𝜇2)
equals 𝜌13|2b = (𝜌13b − 𝜌12b ∗ 𝜌23b ) ∕√1 − (𝜌12b )2√1 − (𝜌23b )2 = 0, it implies that 𝜌13b = 𝜌12b ∗ 𝜌23b . This
reduces the number of parameters in the model that need to be estimated and also simplifies the relation-
ships between the parameters and hyperparameters of the model with the elements of the between-study
covariance matrix:
𝜓21 = 𝜏
2
1 , 𝜓
2
2 = 𝜏
2
2 − 𝜆
2
21𝜏
2
1 , 𝜓
2
3 = 𝜏
2
3 − 𝜆
2
32𝜏
2
2 ,
𝜆21 = 𝜌12b
𝜏2
𝜏1
, 𝜆32 = 𝜌23b
𝜏3
𝜏2
,
(13)
which both can have an advantage in scenarios with multiple outcomes beyond trivariate case as
discussed in Section 5. Similarly as in the case of the full unstructured covariance matrix, placing prior
distributions directly on the between-study standard deviations 𝜏1(2,3) ∼ N(0, 10)I(0, ) and correlations
𝜌
12(23)
b ∼ dunif (−1, 1) gives implied prior distributions placed on the parameters of the model (12),
𝜓1(2,3) and 𝜆21(32) obtained from the the derived relationship between the two sets of parameters.
The remaining parameters are given non-informative prior distributions 𝜂1 ∼ N(0, 1000), 𝜆20(30) ∼
N(0, 1000). The pooled effects 𝛽1(2,3) on the three outcomes in model (2) are also directly linked to the
model (12); 𝛽1 = 𝜂1, 𝛽2 = 𝜆20 + 𝜆21𝛽1 and 𝛽3 = 𝜆30 + 𝜆32𝛽2. As in the model in Section 2.4, centering of
the true effects on surrogate endpoints can be applied to this models in which case the intercepts would
equal the pooled effects.
Assuming such sequential structure of the treatment effects, that could be measured on the same
outcome at multiple time points, the model can lead to removing some of the measurement error, for
example at time two using time one. We cannot measure the true effect 𝜇2i at time two (only have an
estimate Y2i), so having measurement at time one can improve estimate of measurement at time two. This
can be useful in particular when the treatment effect at time one is measured precisely and at time two
inaccurately, then the prediction at time two may be more precise (due to accounting for the correlation
with outcome one) leading to better prediction at time three.
2.6. Criteria for surrogate markers
Consider first a bivariate case (with one surrogate endpoint, where the first endpoint is surrogate to the
second and the third outcome is removed) as described in the first three lines of Equation (10) or (12).
We can then follow the criteria set out by Daniels and Hughes [2], by which 𝜆21 indicates the association
between the treatment effect measured by the surrogate endpoint and the treatment effect measured by the
second clinical outcome (final outcome in the bivariate case with a single surrogate endpoint), therefore,
we require 𝜆21 ≠ 0. For the association to be perfect, the conditional variance should be zero; 𝜓
2
2 = 0.
Also, we would expect 𝜆20 = 0 (no treatment effect on the surrogate endpoint gives no treatment effect
on the target outcome), otherwise not all of the treatment effect on the target outcome is mediated by
the effect on the surrogate endpoint. In the trivariate case with two surrogate markers, the effects of treat-
ment on all biomarkers may jointly mediate the treatment effect on the final outcome. For the combined
effect on the biomarkers to fully mediate the effect on the target outcome, we expect the intercept 𝜆30 = 0
and the conditional variance 𝜓23 = 0. The association between the effect on target outcome and each of
the surrogate endpoints is expected not to be zero; 𝜆31,32 ≠ 0. In the sequential scenario of conditionally
independent effects (described in Section 2.5), the same criteria as in the bivariate case apply, where the
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effect on the first outcome is a surrogate to the effect on the second and the effect on the second out-
come is a surrogate to the effect on the third (final) outcome, but with additional ‘borrowing of strength’
across outcomes by taking into account the correlation structure between all of the outcomes (i.e. only
conditional independence assumed).
2.7. Implementation in WinBUGS and R
All models were implemented in WinBUGS [23] where the estimates were obtained using MCMC
simulation using 50 000 iterations (including 20 000 burn-in). Convergence was checked by visually
assessing the history, chains and autocorrelation using graphical tools in WinBUGS. All posterior esti-
mates are presented as means with the 95% credible intervals (CrI). R was used for data manipulation
and to execute WinBUGS code multiple times (for validation of surrogates for each study) using the
R2WinBUGS package [24]. OpenBUGS and R2OpenBUGS version of the software was used for the
simulation study which was conducted using Linux (Red Hat, Inc., Raleigh, North Carolina)-based high
performance computer.
WinBUGS programs corresponding to the two TRMA models (applied to data in Tables I and II) are
included in Web Supplements A1 and A2.
3. Application: relapsing remitting multiple sclerosis
To illustrate the application of the methods described in Section 2, the models developed there are applied
to the motivating example in RRMS described in Section 3.1. Section 3.2 (along with the Appendix A)
contains details of how data in Table I are used to populate the models for outcomes specific to this
motivating example. Results are presented in Section 3.3.
3.1. Introduction to the motivating example
To illustrate the use of the modelling techniques, we applied them to an example in RRMS. Multiple
sclerosis (MS) is an inflammatory disease of the brain and spinal cord. RRMS is a most common type of
MS. During the course of the disease, patients experience a series of periods of exacerbations (relapses)
and remission. A large proportion of patients (25%) eventually progresses to secondary progressive
disease [25]. The disability progression is considered the final outcome, whereas the number of active
(new or enlarging) T2 lesions in the brain obtained from the magnetic resonance imaging (MRI) and the
annualised relapse rate are two potential surrogate endpoints. This example is based on work by Sormani
et al. [17] who used meta-analytic approach to evaluate whether the effects on relapse rate and number of
active MRI lesions are good predictors of the treatment effects on disability progression (one surrogate
endpoint at a time). In another paper, Sormani et al. [26] investigated estimates of the treatment effect
on number of active MRI lesions as predictors of the effects on relapse rate. Subsequently, Sormani and
colleagues used IPD to investigate individual-level association between outcomes, where they validated
the number of MRI lesions as a surrogate to the number of relapses [27]. In another paper, Sormani et al.
also used IPD to validate both the number of active MRI lesions and the number of relapses as surrogate
endpoints to the disability progression, as individual surrogates as well as joint mediators of the treat-
ment effect on progression [11]. In the papers mentioned previously, the meta-analytic work on study
level was conducted using weighted linear regression [17,26], whereas the association on the individual
level was conducted using Prentice’s criteria [11, 27].
This example with two surrogate endpoints, where one of the candidate surrogate endpoints (to
the final outcome) is also a potential surrogate endpoint to the second surrogate, serves as a desirable
illustration of modelling techniques investigated in this paper. We collect data on the treatment effects
on those outcomes from studies included in the analysis by Sormani et al. [17]. To investigate the surro-
gate endpoints jointly, we chose to include only the studies reporting treatment effect estimates on all of
the three outcomes and those that reported sufficient information to obtain uncertainty estimates around
the observed treatment effect. As a result, we obtained data from 13 studies, 11 placebo-controlled tri-
als and two active-controlled trials, which are listed in Table I and displayed graphically in Figure 2. To
obtain the within-study correlations between the treatment effect estimates for the outcomes, we use the
estimates of Prentice’s criteria, reported by Sormani et al. [27] for the association between the number of
MRI lesions and the number of relapses who adopted the model (6) to those outcomes on log scale and
for the association of both the number of MRI lesions and the relapses with the disability progression
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 1063–1089
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Table II. Indicators of individual-level surrogacy for number of active MRI lesions and relapse rate
as surrogate endpoints to disablity progression (reproduced from Sormani et al [11]) and number of
active MRI lesions as a surrogate endpoint to relapse rate (reproduced from Sormani et al [27]).
Surrogate Final
Prentice’s criteria
endpoint outcome 1st criterion∗ 2nd criterion† 4th criterion‡
active T2 lesions disability progression 𝛼1 = −0.93(0.12) 𝛽1 = −0.37(0.19) 𝛽S1 = −0.14(0.19)
relapses disability progression 𝛼2 = −0.44(0.08) 𝛽2 = −0.37(0.19) 𝛽S2 = −0.15(0.20)
active T2 lesions relapses 𝛼3 = −0.90(0.13) 𝛽3 = −0.36(0.08) 𝛽S3 = −0.17(0.09)
Coefficients are reported with standard errors.
∗1st Prentice’s criterion, treatment is effective on surrogate endpoint.
†2nd Prentice’s criterion, treatment is effective on final clinical outcome.
‡4th Prentice’s criterion, treatment effect on final clinical outcome fully mediated by surrogate.
𝛼1, treatment effect on log number of MRI lesions over 1 year; 𝛼2, treatment effect on log relapse rate
over 1 year; 𝛼3, treatment effect on log number of MRI lesions over 2 years; 𝛽1, 𝛽2, treatment effect on
log odds disability progression over 2 years; 𝛽3, treatment effect on log relapse rate over 2 years.
𝛽S1 and 𝛽S2, treatment effect on log odds disability progression over 2 years adjusted for treatment effect on
log number of MRI lesions and log relapse rate, respectively; 𝛽S3, treatment effect on log relapse rate
over 2 years adjusted for treatment effect on log number of MRI lesions.
Figure 2. Graphical representation of data for treatment effects on MRI (surrogate endpoint 1), relapse rate
(surrogate endpoint 2) and disability progression (final clinical outcome).
reported by Sormani et al. [11], also on log scale. Relevant estimates are listed in Table II. Because of
limitation of the data, in this paper, the correlation is assumed constant across studies.
3.2. Scale of the outcomes and the within-study model
The relative treatment effects on each outcome (MRI, relapse rate and disability progression) and the
within-study variances for the treatment effects in each study are calculated using data listed (and notation
described) in Table I.
The MRI effect is modelled on the log rate ratio (RR) scale, Y1i = logMRIRR = log(RmE∕RmC). The
relative treatment effect on relapses is modelled by the log annualised relapse rate ratio (ARRR) scale,
Y2i = logARRR = log
(
ARRE
ARRC
)
. The relative treatment effect on disability progression is modelled on the
log odds ratio (OR) scale, Y3i = logOR = log
(
RdE(NdC−RdC)
RdC(NdE−RdE)
)
.
The corresponding variances are obtained from the data by the use of delta method for the effects on
MRI and relapses and using the standard formulae for the standard error of logOR, as shown in Appendix
A.1. The within-study correlations are obtained following methods described in Section 2.2, with details
of the algebra for the data in RRMS in Appendix A.2. The correlations were obtained for one study and
assumed the same in all the studies.
Note that some authors used relative risk to quantify the treatment effect on the disability progres-
sion. However, log OR scale is applied here in order to combine the summary data on effectiveness with
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 1063–1089
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reported Prentice’s criteria, which were modelled for the progression on the log odds scale. Typically,
progression is reported cross-sectionally as a number (or proportion) of patients who progressed
(i.e. whose expanded disability status scale score had increased by at least one point at the follow up). As
such, the reported outcome is not suitable to model as time to event outcome on the hazard ratio scale.
3.3. Results
Applying the aformentioned formulae to the RRMS data in Table I and combining it with data of
individual-level surrogacy criteria in Table II gives the within-study correlations: 𝜌12wi = 0.25, 𝜌
13
wi = 0.09,
𝜌23wi = 0.09. The data are applied using the above models to validate surrogate endpoints as predictors of
the clinical benefit on the final outcome using a cross-validation procedure as described in Section 2.1.
First, the models (1) and (10), assuming that all true effects are correlated, is applied. Results of this
application are presented in Section 3.3.1. Then the models (1) and (12), assuming the conditional inde-
pendence between the effects on the final outcome and the first surrogate endpoint is applied and results
presented in Section 3.3.2.
3.3.1. Results from the model with unstructured between-study covariance matrix. To quantify the
surrogacy criteria overall, the model was first applied to the full data (no outcome missing for any of the
studies). The results (parameters with the 95% CrIs) are shown in Table III (top). The coefficients 𝜆20
and 𝜆21 and variance 𝜓
2
2 represent the association between the treatment effect on the number of active
MRI lesions and the effect on the relapse rate, whereas the coefficients 𝜆30, 𝜆31, 𝜆32 and 𝜓
2
3 describe how
the effects on number of MRI lesions and relapse jointly mediate the effect on the disability progression
(as described in Section 2.6). The parameters on the left-hand-side indicate that there was a poor associa-
tion between the effects on MRI and effects on relapses, as the interval of the slope contains zero and the
variance 𝜓23 appears greater than zero. The parameters on the right-hand-side suggest that the association
between the effects on both surrogate endpoints (MRI and relapse rates) are not strongly associated with
the effect on disability progression (slopes contain zero), however, the variance appears small suggesting
that the effect on MRI and relapse rate largely mediate the effect of the treatment on disability progres-
sion. In both cases, the CrIs for the intercepts contain zero, which is encouraging in the sense that zero
treatment effect on MRI would be expected to predict zero effect on relapse rate in the first case and the
zero effects measured by the MRI and relapse rate would lead to predicted zero effect on the disability
progression in the second case. However, in both cases the CrIs are wide, hence, the predictions may not
be accurate.
After estimating the surrogacy criteria using the full data, the cross-validation process was carried out.
The results of the validation are presented in Table IV (column four, along with the results from the bivari-
ate model and trivariate with structured covariance matrix), which shows the values of observed effects
on the final outcome in each study (column two) and the effects on the final outcome predicted by the
model from the effects on the surrogates (given full data on all other studies) with the 95% CrIs. In each
row, the values correspond to the validation of prediction for a study whose corresponding observed effect
on the final outcome is in the second column. In the take-one-out approach of the cross-validation proce-
dure, the regression parameters (the intercepts, slopes and conditional variances, as in the between-study
model (10)) did not change substantially. The full set of those values is included in the Web Supplement
B. The predicted intervals contain the observed value of the treatment effect on the final outcome for all
of the studies confirming good fit of the model.
Table III. Surrogacy criteria obtained from the trivariate models
applied to the full data (no missing outcomes).
Parameter Mean (95% CrI) Parameter Mean (95% CrI)
Unstructured between-study covariance
𝜆20 −0.28 (−0.73, 0.16) 𝜆30 −0.09 (−0.38, 0.21)
𝜆21 0.26 (−0.12, 0.65) 𝜆31 0.00 (−0.38, 0.31)
𝜆32 0.43 (−0.02, 1.06)
𝜓22 0.15 (0.05, 0.37) 𝜓
2
3 0.02 (0.00, 0.10)
Structured between-study covariance
𝜆20 −0.24 (−0.70, 0.20) 𝜆30 −0.06 (−0.31, 0.19)
𝜆21 0.30 (−0.09, 0.70) 𝜆32 0.48 (0.11, 0.88)
𝜓22 0.15 (0.05, 0.36) 𝜓
2
3 0.02 (0.00, 0.10)
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Table IV. Comparison of results of validation obtained from the two trivariate models and a bivariate model.
Predicted
Trivariate Trivariate
Study Observed Bivariate Unstructured % red. Structured % red.
Paty (A) 1.00 (0.57, 1.74) 0.86 (0.42 ,1.74) 0.86 (0.43, 1.73) 0.67 0.88 (0.44, 1.73) 3.16
Paty (B) 0.64 (0.36, 1.16) 0.76 (0.37, 1.56) 0.77 (0.38, 1.54) 2.24 0.77 (0.38, 1.54) 3.29
Simon 0.53 (0.27, 1.06) 0.78 (0.36, 1.73) 0.80 (0.36, 1.77) 0.19 0.79 (0.37, 1.72) 2.10
Millefiorini 0.13 (0.02, 0.67) 0.62 (0.11, 3.46) 0.65 (0.12, 3.62) −0.29 0.62 (0.11, 3.44) 0.32
Li (C) 0.73 (0.47, 1.12) 0.79 (0.43, 1.45) 0.79 (0.45, 1.41) 4.46 0.80 (0.45, 1.42) 5.19
Li (D) 0.63 (0.41, 0.98) 0.79 (0.43, 1.44) 0.81 (0.44, 1.50) −1.07 0.79 (0.45, 1.39) 7.23
Polman 0.50 (0.36, 0.69) 0.59 (0.32, 1.11) 0.61 (0.35, 1.07) 9.67 0.58 (0.33, 1.03) 8.62
Comi (E) 0.64 (0.45, 0.92) 0.62 (0.35, 1.11) 0.62 (0.36, 1.08) 3.71 0.62 (0.36, 1.07) 5.13
Comi (F) 0.69 (0.49, 0.97) 0.64 (0.36, 1.13) 0.64 (0.38, 1.09) 5.77 0.63 (0.37, 1.08) 5.93
Rudick 0.73 (0.56, 0.95) 0.62 (0.37, 1.05) 0.61 (0.37, 1.01) 4.18 0.61 (0.38, 0.98) 10.01
Sorensen 0.57 (0.24, 1.36) 0.62 (0.24, 1.64) 0.64 (0.23, 1.82) −7.52 0.63 (0.24, 1.66) 0.63
Clanet 1.00 (0.75, 1.33) 0.89 (0.49, 1.63) 0.88 (0.49, 1.58) 3.21 0.92 (0.53, 1.60) 8.30
Mikol 1.39 (0.87, 2.23) 0.82 (0.44, 1.55) 0.83 (0.45, 1.53) 2.65 0.85 (0.46, 1.57) 3.45
average % reduction in CrI 2.14% 4.87%
DIC 350.1 347.9
The % red refers to the percentage reduction in the width of the credible interval corresponding to the prediction from
the trivariate model, with the unstructured (columns 4 and 5) or structured (columns 6 and 7) between-study covariance
matrix, compared with the width of the interval corresponding to the prediction from the bivariate model (column 3).
DIC, deviance information criteria.
3.3.2. Results from the model with structured between-study covariance matrix. Models (1) and (12)
with structured between-study covariance matrix, where the effect on the disability progression (the final
outcome) is conditionally independent from the effect on the MRI (the first surrogate endpoint) condi-
tional on the effect on relapse rate (the second surrogate endpoint) is now used for validation. Similarly
as in the case of the model with unstructured covariance matrix, the surrogacy criteria are estimated using
the full data, which is then followed by the cross-validation. In Table III (bottom) the parameters are
shown together with the 95% CrIs for the model applied to the full data. The parameters 𝜆20, 𝜆21 and
𝜓22 describe the association between the treatment effects on the MRI and the relapse rate, while 𝜆30, 𝜆31
and 𝜓23 the association between the treatment effects on the relapse rate and the disability progression
(conditional on the effect on MRI). The association between the effects on the MRI and the relapse rate
is not strong which is indicated by the interval of 𝜆21 containing zero and the variance 𝜓
2
2 significantly
larger than zero. However, the association between the effect on the relapse rate, as a surrogate endpoint,
with the effect on the disability progression, as the final outcome, (conditional on the effect on MRI)
appears strong as indicated by the non-zero slope 𝜆31 and the small variance 𝜓
2
3 . Also the interval of the
intercept 𝜆30 containing zero indicates that zero effect on the relapse rate is likely to imply zero effect on
the disability progression. In the take-one-out approach of the cross-valdation procedure, the regression
parameters (the intercepts, slopes and conditional variances, as in the between-study model (12)) did not
change substantially. The full set of those values is included in the Web Supplement B. Table IV shows
the results of cross-validation (with column six corresponding to predictions from the model with struc-
tured between-study covariance). The results of predictions are similar to those obtained from the model
with unstructured between-study covariance matrix.
3.3.3. Comparison of the results from the two models and those from a bivariate model. When carrying
out the cross-validation process, wewant to ensure that not only predicted CrIs contain the actual observed
values but also that the intervals are narrow. Inclusion of multiple surrogate endpoints can potentially
lead to reduced intervals and hence better predictions. To compare the aforementioned results of the val-
idation from the two trivariate models, they are shown side by side in Table IV as well as graphically in
Figure 3 alongside those from a bivariate model with the effect on the relapse rate as a surrogate for the
effect on the disability progression. In Table IV, apart from the predicted values, the percentage reduc-
tion in the width of the credible interval relative to the width of the interval obtained from the bivariate
model is shown for both trivariate models. On average, the model with the unstructured between-study
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Figure 3. Forest plot, showing for each study the observed value of the OR of disability progression with
corresponding confidence interval (CI) and the predicted valueswith corresponding credible intervals (CrIs) from a
bivariate model, trivariate model with unstructured covariancematrix and from the trivariate model with structured
covariance matrix.
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covariance matrix gave intervals 2% narrower than those from the model using a single surrogate end-
point, whereas the model with the structured covariance matrix led to 5% reduction in uncertainty.
Although the average gain in precision is modest, the inclusion of both surrogates does improve the pre-
dictions and this reduction in uncertainty may be sufficient to improve the decision making process based
on such predictions. This may be the case in particular for larger studies, such as by Polman, Rudick and
Clanet in our illustrative example, where the gain in precision was also larger, up to 10%, likely due to
the treatment effect on the surrogate endpoints being measured with larger precision compared with the
smaller studies. Inclusion of multiple surrogate endpoints may lead to a more substantial gain in preci-
sion in other disease areas and when data on some outcomes in some of the studies are missing at random
[28]. Deviance information criteria (DIC) obtained for the two trivariate models using the complete data,
showed at the bottom of Table IV, suggests that the fit by both models is comparable. The model assum-
ing conditional independence is simpler and easier to implement as shown in Section 5. It also requires
fewer parameters to estimate as discussed further in Section 6. If such assumption can be justified, the
model with the structured covariance may be more practical.
4. Simulation and sensitivity analysis
4.1. Methods
A simulation study was carried out to compare the performance of the three models: a bivariate model
with a single surrogate endpoint and the two trivariate models with two surrogate endpoints, the model
with unstructured between-study covariance matrix and with the structured covariance matrix. Data were
simulated under two scenarios considering alternative covariance structures: unstructured, by simulating
data from the model (1)+(10) and structured by simulating data from the model (1)+(12). The parameters
of the between-study model were set to be comparable with those corresponding to the RRMS data,
namely, 𝜏1,2,3 = 0.5 and 𝜌
12,13,23
b = 0.8 and 𝜂1 = −0.3.
The regression coefficients and the conditional variances were obtained from the between-study stan-
dard deviations and correlations following the formulae (11) and (13) for the models with unstructured
and structured covariance matrices, respectively. The within-study correlations 𝜌jkwi were set to the same
values as in the example in RRMS (obtained from the Prentice’s criteria). Thewithin-study varianceswere
simulated by drawing the precisions (inverse variances) from the gamma distributions; 𝜎1(2,3)i = 1∕P1(2,3)i,
P1(2,3)i ∼ Γ(𝛼1(2,3), 𝜃1(2,3)), where 𝛼1(2,3) are the shape parameters and 𝜃1(2,3) the scale parameters, which
were obtained using the method of moments: E(P1,2,3) = 𝛼1,2,3∕𝜉1,2,3, V(P1,2,3) = 𝛼1,2,3∕𝜉21,2,3, where
𝜉1,2,3 = 1∕𝜃1,2,3 is a rate parameter. By summarising the inverse variances from the RRMS data, the
following parameters were obtained: E(P1) = 30, E(P2) = 150, E(P3) = 25, V(P1) = 420, V(P2) =
15 000 and V(P2) = 275, giving the following shape and rate parameters: 𝛼1 = 2.14, 𝛼2 = 1.5, 𝛼3 = 2.3,
𝜉1 = 0.07, 𝜉2 = 0.01 and 𝜉3 = 0.09. Because of the structure of the gamma distribution, some of
the simulated precisions were very close to zero, resulting in very large variances. This led to some
problems with the estimation. To overcome this issue, a constraint was placed on the simulated value
of the precision by discarding the precisions resulting in variances larger than 2 (this number was taken
as an arbitrary cut off, large enough to be much larger than the variances in the RRMS data and hence
including all plausible variances in the population but small enough not to produce problems with the
estimation). R code for the data simulation is included in the Web Supplement C.
The cross-validation procedure is applied to each simulated data set. This time, however, the
true effect 𝜇3n in a validation study n is known as it has been simulated, so the cross-validation
can be performed on the true effects (which in real circumstances we would like to predict)
by comparing the simulated 𝜇3n with predicted interval of ?̂?3n with the corresponding variance
var(?̂?3n|Y1n,Y2n, 𝜎1n, 𝜎2n,Y1(−n),Y2(−n),Y3(−n)). The two trivariate models and also the bivariate model are
applied to the simulated data sets to compare their performance, by estimating bias of the mean ?̂?3n, root-
mean-square error (RMSE), coverage of 95% credible intervals (CrI) and the potential reduction of the
width of the predicted interval by calculating the ratios of the width of the interval from a trivariate model
w3d (with two surrogate endpoints) with the width of the predicted interval from the bivariate model w2d.
4.2. Sensitivity analysis
To investigate the sensitivity of the methods to the assumption of normality of the data, another simulation
study was carried out where the data were simulated from multivariate t-distribution as well as mixture
normal distribution.
© 2015 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd. Statist. Med. 2016, 35 1063–1089
1077
S. BUJKIEWICZ ET AL.
4.2.1. Simulation study with t-distribution. To simulate data from the t-distribution with unstructured
covariance matrix, the true treatment effects on the three outcomes were generated from the following
model: ⎧⎪⎪⎨⎪⎪⎩
𝜇1i ∼ t(𝜂1, 𝜈1, df )
𝜇2i ∣ 𝜇1i ∼ t(𝜂2i, 𝜈2, df )
𝜂2i = 𝜆20 + 𝜆21𝜇1i
𝜇3i ∣ 𝜇1i, 𝜇2i ∼ t(𝜂3i, 𝜈3, df )
𝜂3i = 𝜆30 + 𝜆31𝜇1i + 𝜆32𝜇2i,
(14)
and from the t-distribution with structured covariance matrix, from the following model
⎧⎪⎪⎨⎪⎪⎩
𝜇1i ∼ t(𝜂1, 𝜈1, df )
𝜇2i ∣ 𝜇1i ∼ t(𝜂2i, 𝜈2, df )
𝜂2i = 𝜆20 + 𝜆21𝜇1i
𝜇3i ∣ 𝜇1i, 𝜇2i ∼ t(𝜂3i, 𝜈3, df )
𝜂3i = 𝜆30 + 𝜆32𝜇2i,
(15)
where 𝜈1,2,3 =
(
𝜓21,2,3(df − 2)
)
∕df and df = 4. The individual study estimates were simulated from the
trivariate t-distribution
⎛⎜⎜⎝
Y1i
Y2i
Y3i
⎞⎟⎟⎠ ∼ MVt
⎛⎜⎜⎝
⎛⎜⎜⎝
𝜇1i
𝜇2i
𝜇3i
⎞⎟⎟⎠ ,𝚺𝐢, df
⎞⎟⎟⎠ , 𝚺𝐢 =
⎛⎜⎜⎜⎝
𝜎21i 𝜎1i𝜎2i𝜌
12
wi 𝜎1i𝜎3i𝜌
13
wi
𝜎2i𝜎1i𝜌
12
wi 𝜎
2
2i 𝜎2i𝜎3i𝜌
23
wi
𝜎3i𝜎1i𝜌
13
wi 𝜎3i𝜎2i𝜌
23
wi 𝜎
2
3i
⎞⎟⎟⎟⎠ . (16)
The simulation was conducted in R software using the rt command (and scaling the simulated data by
𝜓1,2,3
√
((df − 2)∕df ) + 𝜂1) for univariate t-distributions in the between-study models (14) and (15) and
the rmvt in the within-study model (16).
4.2.2. Simulation study with mixture normal distribution. Data with more severe departure from nor-
mality were generated by the use of mixture normal distributions. This was achieved by replacing the
univariate normal distribution for the true treatment effect on the first outcome in the models (10) and
(12) with the mixture normal distribution
𝜇1i ∼ p1 ∗ N
(
𝜂1, 𝜓
2
1
)
+ p2 ∗ N
(
𝜂1 − 4 ∗ 𝜓1, 𝜓21
)
+ p3 ∗ N
(
𝜂1 + 4 ∗ 𝜓1, 𝜓21
)
, (17)
with p1 = 0.5, p2 = 0.3 and p3 = 0.2. This deviation from normality feeds through to the true effects 𝜇2i
and 𝜇3i by the linear association of those effects with 𝜇1i. These now non-normal true effects 𝜇1(2,3)i are
then used as mean values when generating the within study data from the multivariate normal distribution
giving data with ‘distorted’ normality.
4.3. Results
Data sets including the treatments effects (and corresponding sampling variances) on three outcomes in
15 studies were generated in 1000 simulations for each scenario. 0.1% of simulation runs were discarded
because of precisions resulting in too high variances, as explained in the methods Section 4.1. Simu-
lation results are presented in Table V. The bias of mean predicted effect ?̂?3n for a validation study n
was comparable across all models and data scenarios. The RMSE was larger when data were simulated
from a model with unstructured covariance matrix, regardless of the distribution or model fitted to the
data. All models (the bivariate and the two trivariate) seemed to perform equally well, giving coverage
of 95% credible interval close to 95% for most scenarios, except for the data generated from the mixture
normal distribution where the coverage was slightly inflated to 98% (because of the three normal distribu-
tions being approximated by models with a single normal distribution, leading to the inflated variance of
predictions). For data generated from eithermultivariate normal or t-distributionwith unstructured covari-
ance matrix, both trivariate models gave on average 4% reduction of the width of the predicted interval
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Table V. Results of simulation studies.
Meta-analysis Bias of RMSE Coverage of 95% Median
model mean ?̂?3n of ?̂?3n CrI for ?̂?3n w3d∕w2d
Scenario 1: Data simulated from normal TRMA with UCM
BRMA −0.002 0.46 0.96
TRMA UCM 0.003 0.45 0.96 0.96
TRMA SCM −0.001 0.46 0.95 0.96
Scenario 2: Data simulated from normal TRMA with SCM
BRMA 0.006 0.36 0.95
TRMA UCM 0.003 0.36 0.95 0.98
TRMA SCM 0.006 0.35 0.94 0.95
Scenario 3: Data simulated from TRMA with UCM and t-distribution
BRMA −0.002 0.48 0.95
TRMA UCM −0.004 0.47 0.95 0.96
TRMA SCM −0.002 0.48 0.94 0.96
Scenario 4: Data simulated from TRMA with SCM and t-distribution
BRMA −0.0001 0.36 0.95
TRMA UCM 0.002 0.37 0.95 0.98
TRMA SCM 0.0002 0.36 0.94 0.95
Scenario 5: Data simulated from TRMA with UCM and mixture normal
BRMA −0.007 0.49 0.98
TRMA UCM 0.003 0.47 0.98 1.00
TRMA SCM −0.001 0.47 0.97 0.91
Scenario 6: Data simulated from TRMA with SCM and mixture normal
BRMA −0.002 0.36 0.98
TRMA UCM 0.0001 0.37 0.98 1.01
TRMA SCM −0.0001 0.36 0.97 0.91
RMSE, root-mean-squared-error; CrI, credible interval
UCM, unstructured covariance matrix; SCM, structured covariance matrix; TRMA, trivariate
random effects meta-analysis;
w3d (w2d), width of the predicted interval from TRMA (BRMA)
MC errors of the predicted mean effects were less than 0.012 in scenarios 1–4 and less than 0.015
and 0.025 in scenarios 5 and 6, respectively
compared with the intervals obtained from the bivariate model. When data was simulated using normal
or t-distribution with structured covariance matrix, the trivariate model with unstructured covariance
gave on average 2% reduction in uncertainty around the predicted effect compared with the uncertainty
around predictions obtained from the bivariate model, while the model with structured covariance matrix
gave predictions with intervals 5% narrower compared with those obtained from the model with a single
surrogate endpoint. When data were simulated from the mixture of normal distributions, the trivariate
model with unstructured covariance did not produce any gain in precision of predictions, while the model
with structured covariance matrix gave predicted intervals that were on average 9% narrower compared
with those obtained from the bivariate model.
4.4. Discussion of the results
The outcomes of the simulation study were broadly in agreement with those obtained from the case
study. The predicted intervals obtained from TRMAmodels were narrower compared with those obtained
from BRMA, but this reduction was less pronounced when using the TRMA UCM model on the data
simulated from a model with structured covariance matrix (one of the surrogates correlated to the other
surrogate but less so to the final outcome; scenarios 2, 4 and 6 in Table V and also in the RRMS
case study). Using TRMA UCM on data simulated from the same model gives the same reduction in
uncertainty as when using TRMA SCM but this effect of the addition of the second surrogate on the
uncertainty around the predicted effects diminished with the departure from normality (scenario 5).
There was no effect of adding the second surrogate endpoint on the RMSE which was almost the same
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across the three methods within each scenario. When data were simulated from non-normal distribution
(t-distribution or mixture normal) with structured covariance matrix, the RMSE was slightly larger when
using TRMA UCM (compared with BRMA or TRMA SCM). This is likely due to the TRMA UCM
model forcing too rigid correlation structure on the data leading to bias when making predictions for
outlying observations in data with not as strong correlation pattern. When data represents all outcomes
correlated (from a distribution with unstructured covariance matrix), both TRMA models seem to per-
form equally well, with slightly smaller RMSE when using TRMA UCM if the data are normally
distributed. However, for non-normally distributed data, gain in precision is only present when using
TRMA SCM . When data corresponds to the scenario with the structured covariance matrix the TRMA
SCM model seems to perform better than TRMA UCM in terms of both RMSE and the uncertainty of
the predictions.
5. Multivariate random effects meta-analysis
Methodology introduced in Section 2 can be extended to a scenario with multiple surrogate endpoints.
Suppose, we have estimates of treatment effects observed on N outcomes, Y1i,Y2i,… ,YNi in each study i,
and YN is the final clinical outcome of interest, while Y1,… ,YN−1 are intermediate surrogate endpoints.
If the estimates of the treatment effects on all of the outcomes are assumed normally distributed and
correlated, then they follow a multivariate normal distribution:
⎛⎜⎜⎜⎝
Y1i
Y2i
⋮
YNi
⎞⎟⎟⎟⎠ ∼ N
⎛⎜⎜⎜⎝
⎛⎜⎜⎜⎝
𝜇1i
𝜇2i
⋮
𝜇Ni
⎞⎟⎟⎟⎠ ,𝚺𝐢
⎞⎟⎟⎟⎠ , 𝚺𝐢 =
⎛⎜⎜⎜⎜⎝
𝜎21i 𝜎1i𝜎2i𝜌
12
wi · · · 𝜎1i𝜎Ni𝜌
1N
wi
𝜎2i𝜎1i𝜌
12
wi 𝜎
2
2i · · · 𝜎2i𝜎Ni𝜌
2N
wi
⋮ ⋮ ⋱ ⋮
𝜎Ni𝜎1i𝜌
1N
wi 𝜎Ni𝜎2i𝜌
2N
wi · · · 𝜎
2
Ni
⎞⎟⎟⎟⎟⎠
(18)
In the aforementioned model, outcomes Y1i, Y2i, … and YNi are assumed to be estimates of correlated
true effects 𝜇1i, 𝜇2i, … and 𝜇Ni with corresponding within-study covariance matrices 𝚺𝐢 of the esti-
mates. These study-level effects follow a multivariate normal distribution with means
(
𝛽1, 𝛽2,… , 𝛽N
)
and covariance 𝐓,
⎛⎜⎜⎜⎝
𝜇1i
𝜇2i
⋮
𝜇Ni
⎞⎟⎟⎟⎠ ∼ N
⎛⎜⎜⎜⎝
⎛⎜⎜⎜⎝
𝛽1
𝛽2
⋮
𝛽N
⎞⎟⎟⎟⎠ ,𝐓
⎞⎟⎟⎟⎠ , 𝐓 =
⎛⎜⎜⎜⎜⎝
𝜏21 𝜏1𝜏2𝜌
12
b · · · 𝜏1𝜏N𝜌
1N
b
𝜏2𝜏1𝜌
12
b 𝜏
2
2 · · · 𝜏2𝜏N𝜌
2N
b
⋮ ⋮ ⋱ ⋮
𝜏N𝜏1𝜌
1N
b 𝜏N𝜏2𝜌
2N
b · · · 𝜏
2
N
⎞⎟⎟⎟⎟⎠
. (19)
In this hierarchical framework, Equations (18) and (19) describe the within-study and the between-study
models, respectively. The between-study model can be reparameterised to extend the scenarios for mod-
elling of surrogate endpoints described in Sections 2.3, 2.4 and 2.5 to the multivariate case, using the
unstructured and structured covariance matrices.
5.1. Product normal formulation with unstructured covariance matrix
Assuming that true treatment effects on all the outcomes are correlated, we can parameterise the between-
study model (19) in the form of product normal formulation by extending model (10) to
⎧⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎩
𝜇1i ∼ N
(
𝜂1, 𝜓
2
1
)
𝜇2i ∣ 𝜇1i ∼ N
(
𝜂2i, 𝜓
2
2
)
𝜂2i = 𝜆20 + 𝜆21𝜇1i
𝜇3i ∣ 𝜇1i, 𝜇2i ∼ N
(
𝜂3i, 𝜓
2
3
)
𝜂3i = 𝜆30 + 𝜆31𝜇1i + 𝜆32𝜇2i
⋮
𝜇Ni ∣ 𝜇1i, ..., 𝜇(N−1)i ∼ N
(
𝜂Ni, 𝜓
2
N
)
𝜂Ni = 𝜆N0 + 𝜆N1𝜇1i + · · · + 𝜆N(N−1)𝜇(N−1)i.
(20)
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In this model, prior distributions need to be placed on all the parameters. Non-informative normal dis-
tributions are placed on the mean effect 𝜂1 ∼ N(0, 1000) and the intercepts 𝜆20,… , 𝜆N0 ∼ N(0, 1000).
Similarly as in the trivariate case, we place prior distributions on the between-study correlations and
between-study standard deviations (elements ofmatrix T in (19) for whichwe aremore likely to anticipate
a range of values or, in some applications can obtain an external information to construct informative prior
distributions for them). The relationships between the model hyper-parameters (conditional variances
𝜓21 , 𝜓
2
2 ,… , 𝜓
2
N and slopes 𝜆21, 𝜆31, 𝜆32,… , 𝜆N1, 𝜆N2,… , 𝜆N(N−1)) and the between-study parameters
(correlations and standard deviations) give implied prior distributions for those hyper-parameters and
also ensure that the between-study covariance is positively defined,
⎧⎪⎪⎪⎨⎪⎪⎪⎩
𝜓21 = 𝜏
2
1
𝜓22 = 𝜏
2
2 − 𝜆
2
21𝜏
2
1
𝜓23 = 𝜏
2
3 − 𝜆
2
31𝜏
2
1 − 𝜆
2
32𝜏
2
2
⋮
𝜓2N = 𝜏
2
N − 𝜆
2
N1𝜏
2
1 − 𝜆
2
N2𝜏
2
2 − · · · − 𝜆
2
N(N−1)𝜏
2
N−1.
(21)
⎧⎪⎪⎪⎪⎨⎪⎪⎪⎪⎩
𝜆21 = 𝜌12b 𝜏2∕𝜏1
𝜆31 = 𝜌13b 𝜏3∕𝜏1 − 𝜆21
𝜆32 =
(
𝜌23b 𝜏2𝜏3 − 𝜆21𝜆31𝜏
2
1
)
∕𝜏22
⋮
𝜆NQ =
(
𝜌
QN
b 𝜏Q𝜏N −
N−1∑
P=1,P≠Q
𝜆NQCov(𝜇P, 𝜇Q)
)
∕𝜏2Q
(22)
These relationships are obtained by calculating the variances and correlations in terms of the hyperpa-
rameters and rearranging the equations for the variances and solving the set of simultaneous equations
for correlations. Details are given in Appendix B.1. This becomes a complex task in higher dimensions.
Alternative and simpler model can be used by assuming a structure of the between-study covariance
matrix as described in Section 5.2.
5.1.1. Criteria for surrogate markers. In the case of multiple endpoints with N − 1 surrogate markers,
the effects of treatment on all biomarkers may jointly mediate the treatment effect on the target outcome.
For the combined effect on the biomarkers to fully mediate the effect on the target outcome, we expect
the intercept 𝜆N0 = 0 and the conditional variance 𝜓2N = 0. The association between the effect on target
outcome and each of the surrogate endpoints is expected not to be zero; 𝜆NX ≠ 0, (X = 1,… ,N − 1).
Similarly, the relationship between effects on other outcomes can be investigated. For example, if we
consider outcomes Y1 to YM−1 to be potential surrogates to outcome YM (M < N), then coefficients for
𝜂Mi, namely, 𝜆M0, 𝜆M1,… , 𝜆M(M−1) and 𝜓2M , are investigated in the same manner, giving an option for
considering multiple ‘final’ endpoints at the same time.
5.2. Product normal formulation with structured covariance matrix
Scenariowith two surrogate endpoints and final outcomemeasured ‘in sequence’, described in Section 2.5
can be extended to the multivariate case. If we imagine that theN outcomes are ordered in a sequence (for
example according to measurement time or other reasons that would impose such correlation structure),
a conditional independence between any pair of outcomes that are not ‘neighbours’ can be assumed,
conditional on the outcomes placed in the sequence in between that particular pair.
This leads to a structure being placed on the between-study covariance matrix in such a way to fully
take into account of the correlations between the treatment effect on pairs of outcomes (for example those
that are measured one after another in a time sequence, but assume conditional independence of other
effects). The elements of the precision matrix T−1 corresponding to the effects that are conditionally
independent become zero and only those on diagonal and immediate off-diagonals are non-zero. The
between-study model (19) is then parameterised in the product normal,
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⎧⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎩
𝜇1i ∼ N
(
𝜂1, 𝜓
2
1
)
𝜇2i ∣ 𝜇1i ∼ N
(
𝜂2i, 𝜓
2
2
)
𝜂2i = 𝜆20 + 𝜆21𝜇1i
𝜇3i ∣ 𝜇2i ∼ N
(
𝜂3i, 𝜓
2
3
)
𝜂3i = 𝜆30 + 𝜆32𝜇2i
⋮
𝜇Ni ∣ 𝜇(N−1)i ∼ N
(
𝜂Ni, 𝜓
2
N
)
𝜂Ni = 𝜆N0 + 𝜆N(N−1)𝜇(N−1)i,
(23)
Similarly as in previous models (the trivariate and the multivariate with unstructured between-study
covariance), the parameters of the above model can be expressed in terms of the elements of the between-
study covariance matrix 𝐓 (19):
𝜓21 = 𝜏
2
1 , 𝜓
2
2 = 𝜏
2
2 − 𝜆
2
21𝜏
2
1 , 𝜓
2
3 = 𝜏
2
3 − 𝜆
2
32𝜏
2
2 , … , 𝜓
2
N = 𝜏
2
N − 𝜆
2
N(N−1)𝜏
2
N−1 (24)
and ⎧⎪⎪⎨⎪⎪⎩
𝜆21 = 𝜌12b
𝜏2
𝜏1
𝜆32 = 𝜌23b
𝜏3
𝜏2
⋮
𝜆N(N−1) = 𝜌
(N−1)N
b
𝜏N
𝜏(N−1)
(25)
obtained from the formulae for the correlations in Appendix B.1. Non-informative prior distributions
are then placed on the between-study correlations and standard deviations, 𝜌12b , 𝜌
23
b , 𝜌
34
b ,… , 𝜌
(N−1)N
b ∼
dunif (−1, 1), 𝜏1,… , 𝜏N ∼ N(0, 10)I(0, ), as well as the remaining, independent parameters, 𝜂1 ∼
N(0, 1000), 𝜆20,… , 𝜆N0 ∼ N(0, 1000). In this form, the model is much easier to implement compared
with the model with the unstructured covariance matrix in Section 5.1.
6. Discussion
We have developed a multivariate meta-analytic framework to include multiple surrogate endpoints
when predicting the treatment effect on the final clinical outcome in an early drug evaluation process.
The validation process discussed here aims to evaluate how well the effect of a treatment on multiple
surrogate endpoints can jointly predict treatment effect on the final clinical outcome. Two approaches
were developed, one assuming all effects being correlated giving an unstructured between-study covari-
ancematrix and amodel assuming conditional independence between the effects on some of the endpoints
giving a structured covariance matrix. The first model makes fewer assumptions about the data but
requires estimation of a large number of parameters (which may be difficult if the number of studies is
relatively low) and also may be difficult to implement in higher dimensions. The second model makes
an assumption of conditional independence of some effects but leads to a reduced number of parameters
to estimate and is easier to implement as the relationships between the parameters of the model and the
elements of the between-study covariance matrix have a simple form. For example, in a scenario with
five endpoints (four surrogate endpoints and one final outcome), the model with unstructured covariance
matrix is set up to estimate five between study variances and ten between-study correlations, while the
model assuming conditional independence with structured between-study covariance matrix estimates
only four between-study correlations. However the assumption of conditional independence of some of
the outcomes may lead to underestimating some correlations which may impact on predictions. This
modelling framework, however, allows for flexible modelling of the correlation structure where a choice
can be made about which correlations need to be fully taken into account. A model ‘in between’ those
two discussed can be implemented, such as the one showed schematically in Figure 4 which extends the
scenario with five endpoints in sequence (structured covariance matrix model) by taking into account of
the correlation between the final and the second to last outcome (now removing the zero from the element
[3,5] of the precision matrix T−1 which was present in the sequential model with conditional indepen-
dence of effects on outcomes three and five). The desirable correlation is taken into account, while an
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Figure 4. Example of a scenario of modellingmultiple surrogate endpoints with a choice of a correlation structure.
assumption of conditional independence of the remaining outcomes is still made thereby reducing the
number of correlations from ten in the model with unstructured covariance matrix to only five. See all
three scenarios represented graphically in the Web Supplement D. The results of the case study and the
simulation study suggest that the choice of the model (in terms of the covariance structure) when made
in line with the correlation structure of the data will lead to better predictions.
Further research is required to extend the aforementioned methodology to more exact methods for
Binomial or count data to relax the assumption of normality, for example, by adopting methods similar
to those introduced by Stijnen et al. [29] using exact likelihood, by means of a generalised linear mixed
models. However, our simulation study showed robustness of the methods to the departures from nor-
mality of the data. Another limitation is the prediction of the treatment effect ‘estimate’ rather than the
true effect. Ideally, we want to know how our predicted treatment effect compares with the true treat-
ment effect. However, although the models have the ability to predict the true effects, such effect cannot
be used for validation based on the real data as the true treatment effect is unknown which limits the
cross-validation to comparing the predicted treatment effect ‘estimates’ with the observed (but pretended
missing) treatment effects for the final outcome.
The approach to validation of surrogate endpoints presented here focusses mainly on validating
the endpoints as good (joint) predictors of the clinical benefit on the final outcome. It is now well
established that the surrogacy has to be validated on both individual and study level. Prentice’s criteria
can be used to validate surrogate endpoints on the individual level when IPD are available. The use of
the Prentice’s criteria to estimate the within-study correlations between the treatment effects on different
outcomes (by assuming one endpoint in each pair of outcomes can be considered a surrogate to the other)
provides a bridge between validation on the two levels. This approach may be useful when the sharing
of patient data from multiple clinical trials is problematic, but owners of the data may be willing to share
Prentice’s criteria.
There are some limitations of Prentice’s criteria for surrogacy. As discussed by a number of authors
[30–32], satisfying those criteria does not guarantee a causal relationship between the treatment effects
on the surrogate and the final outcome. An example of data scenario where Prentice’s fourth criterion is
satisfied but it does not support a claim of causality can be found in Buyse et al, who discuss a number
of approached to evaluation of surrogate endpoints [32]. As pointed out by Joffe and Greene [30], the
statisticalmodel describing the Prentice’s criteria does not account for the common causes of the surrogate
and the final outcomes. The fourth Prentice’s criteria, sometimes referred to as the surrogacy criteria, is
based on the assumption that the treatment effect can be partitioned into direct and indirect effects with
the indirect effect being the part mediated by the surrogate and the direct being the part of the effect
not mediated by the surrogate. Ignoring the common causes by modelling the direct effect on the final
outcome by conditioning on the effect on the surrogate is, however, not equivalent with experimentally
controlling the surrogate, as pointed out by Pearl [33]. As discussed by VanderWeele [31], this can lead
to the ‘surrogate paradox’ where despite the positive association between treatment and the surrogate and
the surrogate and the final outcome, the association between the treatment and the final outcome may be
negative. Chen et al [34] referred to this phenomena as effect reversal.
This issue of the causal effect mostly affects surrogate evaluation when such analysis is based on a
single study. The meta-analytic approach, such as described in our paper, follows the causal association
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paradigm which, as discussed by Joffe and Greene, is based on establishing the association between the
treatment effects on the candidate surrogate endpoint and on the final outcome (rather than modelling
the effect of surrogate on the final outcome) [30]. The authors point out that this approach is more use-
ful for evaluation of surrogate endpoints as it is free from the restrictions of the causal effect paradigm
as the causal association does not require experimental manipulation of the surrogate. The meta-analytic
approach to the causal association study involves associations between quantities that derive directly
from randomisation and as such are average causal effects. Meta-analytic approach, such as proposed in
our study, is based on data from a number of studies or subgroups and is likely to include heterogeneous
treatment contrasts which is an obvious advantage over evaluation based on a single study. Such a single
trial validation cannot guarantee that an association between effects confirmed based on individual data
under one treatment will hold in other interventions. Moreover, Alonso et al, who investigated the rela-
tionship between the causal inference and meta-analytic approaches to the surrogate endpoint evaluation,
have shown that causal effect of the surrogate on the final outcome validated based on a single study
may not be confirmed in the meta-analytic setting, in particular, when the between-study heterogeneity is
large and the causal effect is weak [35]. The authors have also concluded that a surrogate endpoint
that successfully validated in a meta-analytic setting, on both individual and trial level, is likely to be
confirmed when evaluated based on causal inference framework.
In this paper, we used the Prentice’s criteria to estimate the within-study correlation between the
treatment effects, as ignoring the within-study correlation has known consequences [15]. Moreover,
ideally, the correlation should be obtained for each study independently to account for potential
differences in the association depending on the treatment contrast. The main goal in the development of
these models was building a framework under which all available evidence can be used to predict future
treatment effect on the final outcome while taking into account of uncertainty around relevant parameters.
In particular, these approaches have advantage over simple regression models as they take into account
measurement error of the treatment effect on surrogate endpoints ignoring which can impact on predic-
tions [12]. Further research on putting this work in the framework of causal mediation could provide
solution to some of the aforementioned limitations.
Appendix A. Within-study model for relapsing remitting multiple sclerosis
In this Section, the details of how the data in Tables I and II are used to obtain the within-study standard
variances and correlations.
A.1. Within-study variances
The MRI effect is modelled on the log rate ratio (RR) scale,
Y1i = logMRIRR = log(RmE∕RmC) (A.1)
with
𝜎21i = Var(logMRIRR) = Var(logRmE − logRmC) = Var(logRmE) + Var(logRmC), (A.2)
where subscriptC and E stand for the control and experimental arms, respectively. From the delta method
Var(logRmX) =
1
(RmX)2
Var(RmX) =
(
SE(RmX)
RmX
)2
(A.3)
in each arm X.
The relative treatment effect on relapses is modelled by the log annualised relapse rate ratio
(ARRR) scale,
Y2i = logARRR = log
(
ARRE
ARRC
)
(A.4)
with
𝜎22i = Var(logARRR) = Var(logARRE − logARRC) = Var(logARRE) + Var(logARRC), (A.5)
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where ARRX = ARrX∕NrX is the annualised relapse rate in arm X. From delta method
Var(logARRX) = Var(log(RelRateX∕Ft)) = Var(log(RelRateX) − log(Ft))
= Var(log(RelRateX))
= 1
(mean(RelRateX))2
Var(RelRateX)
= 1
mean(RelRateX)
= 12
ARrx × Ft
, (A.6)
where Ft is the follow-up time in months and RelRateX is relapse rate in arm X.
The relative treatment effect on disability progression is modelled on the log odds ratio (OR) scale,
Y3i = logOR = log
(
RdE(NdC − RdC)
RdC(NdE − RdE)
)
(A.7)
with the corresponding variance
𝜎23i = Var(logOR) =
1
RdE
+ 1
NdE − RdE
+ 1
RdC
+ 1
NdC − RdC
. (A.8)
The within-study correlations 𝜌jkwi are required to complete the within-study model. Because the correla-
tions are not available for any of the studies and the IPD are not available for any of the studies, but the
Prentice’s criteria are available for one of the studies (Li for combined cohorts C and D), the approach
derived in Section 2.2.2 is adopted here to calculate the within-study correlations for this particular study
which is then assumed to be the same in all of the studies in meta-analysis.
A.2. Within-study correlations
Let 𝜉 correspond to the index of the study by Li et al.
A.2.1. The within-study correlation between the estimates of the treatment effects on MRI and on the
relapse rate. In this study,
𝜌12w𝜉 = Σ𝜉[1, 2]∕
√
𝜎21𝜉𝜎
2
2𝜉
and the covariance between log MRI RR and log ARRR, Σ𝜉[1, 2] can be expressed as
Σ𝜉[1, 2] = Σ𝜉[2, 1] = Cov(logARRR, logMRIRR)
= Cov(logARRE − logARRC, logRmE − logRmC)
= Cov(logARRE, logRmE) + Cov(logARRC, logRmC) (A.9)
and
Cov(logARRX , logRmX) = Cov(logARrX − logNrX , logRmX)
= Cov(logARrX , logMRmX) − Cov(logNrX , logRmX)
=
√
Var(logARrX)Var(logRmX)𝜌∗MR
−
√
Var(logNrX)Var(logRmX)?̂?MR
=
√
Var(logARrX)Var(logRmX)𝜌∗MR. (A.10)
where the correlation 𝜌∗MR, as discussed in Section 2, equals to the adjusted association obtained using
the formula (8)
𝜌∗MR =
𝛽3 − 𝛽S3
𝛼3
√
𝜔𝜉MM∕𝜔𝜉RR. (A.11)
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Prentice’s criteria for the association between the log MRI rate and log relapse rate (𝛼3, 𝛽3 and 𝛽S3
reported in Table II) were obtained by fitting the model (6) to the full cohort of the study by Li et al.
(rather than separately to the treatment arms). We assume that the correlation is the same in the treat-
ment arms and the whole cohort and hence, the variances 𝜔𝜉MM = Var(logRmE) + Var(logRmC) and
𝜔𝜉RR = Var(logARrE) + Var(logARrC).
A.2.2. The within-study correlation between the estimates of the treatment effects on relapse rate and on
the disability progression. In this study the correlation can be obtained in a similar manner:
𝜌23w𝜉 = Σ𝜉[2, 3]∕
√
𝜎22𝜉𝜎
2
3𝜉
and the covariance between log ARRR and log OR, Σ𝜉[2, 3], can be expressed as
Σ𝜉[2, 3] = Σ𝜉[3, 2] = Cov(logARRR, logOR)
= Cov(logARRE − logARRC, logOPE − logOPC)
= Cov(logARRE, logOPE) + Cov(logARRC, logOPC)
(A.12)
and
Cov(logARRX , logOPX) = Cov(logARrX − logNrX , logOPX)
= Cov(logARrX , logOPX) − Cov(logNrX , logOPX)
=
√
Var(logARrX)Var(logOPX)𝜌∗RP
−
√
Var(logNrX)Var(logOPX)?̂?RP
=
√
Var(logARrX)Var(logOPX)𝜌∗RP
(A.13)
where OPX refers to the odds of progression in arm X and Var(logOPX) =
1
RdX
+ 1
NdX−RdX
. The correlation
𝜌∗RP is the adjusted association obtained using the formula (8)
𝜌∗RP =
𝛽2 − 𝛽S2
𝛼2
√
𝜔𝜉RR∕𝜔𝜉PP. (A.14)
Prentice’s criteria for the association between the log relapse rate and log odds of disability (𝛼2, 𝛽2
and 𝛽S2 reported in Table II) were obtained by fitting themodel (6) to the full cohort of the study by Li et al.
hence, the variances 𝜔𝜉RR = Var(logARRE) + Var(logARRC) and 𝜔𝜉PP = Var(logOPE) + Var(logOPC).
A.2.3. The within-study correlation between the estimates of the treatment effects on MRI and on the
disability progression. In this study the correlation is obtained using similar approach:
𝜌13w𝜉 = Σ𝜉[1, 3]∕
√
𝜎21𝜉𝜎
2
3𝜉
and the covariance between log MRI RR and log OR, Σ𝜉[1, 3] can be expressed as
Σi[1, 3] = Σi[3, 1] = Cov(logMRIRR, logOR)
= Cov(logRmE − logRmC, logOPE − logOPC)
= Cov(logRmE, logOPE) + Cov(logRmC, logOPC) (A.15)
and
Cov(logRmX , logOPX) =
√
Var(logRmX)Var(logOPX)𝜌∗MP, (A.16)
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where
𝜌∗MP =
𝛽1 − 𝛽S1
𝛼1
√
𝜔𝜉MM∕𝜔𝜉PP. (A.17)
Prentice’s criteria for the association between the log MRI rate and log odds of disability (𝛼1, 𝛽1 and 𝛽S1
reported in Table II) were obtained by fitting the model (6) to the full cohort of the study by Li et al.
hence, the variances 𝜔𝜉MM = Var(logRmE) + Var(logRmC) and 𝜔𝜉PP = Var(logOPE) + Var(logOPC).
Appendix B. Relationships between parameters of the N-dimensional model
In this section, we derive the relationships between the model hyper-parameters (conditional variances
𝜓21 , 𝜓
2
2 ,… , 𝜓
2
N and slopes 𝜆21, 𝜆31, 𝜆32,… , 𝜆N1, 𝜆N2,… , 𝜆N(N−1)) and the between-study parameters
(correlations and standard deviations).
B.1. Model with unstructured covariance
In the model with the unstructured covariance the between-study variances have the following forms:
⎧⎪⎪⎨⎪⎪⎩
Var(𝜇1) = 𝜏21 = 𝜓
2
1
Var(𝜇2) = 𝜏22 = 𝜓
2
2 + 𝜆
2
21𝜓
2
1 = 𝜓
2
2 + 𝜆
2
21𝜏
2
1
Var(𝜇3) = 𝜏23 = 𝜓
2
3 + 𝜆
2
31𝜓
2
1 + 𝜆
2
32(𝜓
2
2 + 𝜆
2
21𝜓
2
1 ) = 𝜓
2
3 + 𝜆
2
31𝜏
2
1 + 𝜆
2
32𝜏
2
2
⋮
Var(𝜇N) = 𝜏2N = 𝜓
2
N + 𝜆
2
N1𝜏
2
1 + · · · + 𝜆
2
N(N−1)𝜏
2
N−1,
(B.1)
the covariances are
⎧⎪⎪⎪⎨⎪⎪⎪⎩
Cov(𝜇1, 𝜇2) = 𝜆21Var(𝜇1)
Cov(𝜇1, 𝜇3) = 𝜆31Var(𝜇1) + 𝜆32Cov(𝜇2, 𝜇1)
Cov(𝜇2, 𝜇3) = 𝜆32Var(𝜇2) + 𝜆31Cov(𝜇2, 𝜇1)
⋮
Cov(𝜇Q, 𝜇N) = 𝜆NQVar(𝜇Q) +
N−1∑
P=1,P≠Q
𝜆NPCov(𝜇P, 𝜇Q), Q = 1,… ,N − 1,
(B.2)
and corresponding correlations
⎧⎪⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎪⎩
𝜌12b =
𝜆21𝜏
2
1√
𝜏21 𝜏
2
2
𝜌13b =
𝜆31𝜏
2
1+𝜆32𝜆21𝜏
2
1√
𝜏21 𝜏
2
3
𝜌23b =
𝜆32𝜏
2
2+𝜆31𝜆21𝜏
2
1√
𝜏22 𝜏
2
3
⋮
𝜌
QN
b =
𝜆NQ𝜏
2
Q+
N−1∑
P=1,P≠Q
𝜆NQCov(𝜇P,𝜇Q)√
𝜏2Q𝜏
2
N
, Q = 1,… ,N − 1.
(B.3)
To obtain implied prior distribution for the hyper-parameters, we need to express them in terms of the
between-study correlations and standard deviation. The conditional variances are obtained by rearrang-
ing terms in Equation (B.1) which gives formulae in (21). To obtain formulae for the slopes, the set of
simultaneous Equations (B.3) needs to be solved giving the formulae in (22).
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B.1. Model with structured covariance
In the model with structured covariance matrix, the correlations have a simple form,
⎧⎪⎪⎨⎪⎪⎩
𝜌12b = 𝜆21
𝜏1
𝜏2
𝜌23b = 𝜆32
𝜏2
𝜏3
⋮
𝜌
(N−1)N
b = 𝜆N(N−1)
𝜏(N−1)
𝜏N
,
(B.4)
which lead to also simpler (and easier to calculate and implement) relationships (25), between the slopes
and the between-study parameters.
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